Future studies that address these limitations, incorporating prospective clinical trials and focusing on specific patient subgroups, are crucial for validating the clinical utility of EGFR as a biomarker for GBM diagnosis, prognosis, and treatment stratification. This evidence concerns the gene EGFR and glioblastoma.